Drug intelligence / Profile preview

DA-5222-R1 + DA-5222-R2 + DA-5222-R3

Development stage: Unknown
Lead developer: Dong-A ST
Administration: Oral

Overview

DA-5222-R1 + DA-5222-R2 + DA-5222-R3 is an experimental combination pharmaceutical product being evaluated for its pharmacokinetics and safety in healthy adults. It is being directly compared to the single agent DA-5222 in recent Phase 1 clinical trials. DA-5222-R1, DA-5222-R2, and DA-5222-R3 are administered together as single oral doses (one tablet each once a day), but the detailed composition, mechanism of action, and indication specifics are not disclosed in current public records. All agents are under development by Dong-A ST. No information is available regarding their mechanisms, target, or specific pharmacological classes beyond participation in the described clinical studies[1][2][3][4][5][6][7][9][10].

Beyond the preview

Go deeper on DA-5222-R1 + DA-5222-R2 + DA-5222-R3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-5222-R1 + DA-5222-R2 + DA-5222-R3.

Explore the full profile